Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
Condition:   Herpes Labialis Interventions:   Drug: HDIT101 (blinded therapy);   Drug: Placebo (blinded therapy);   Behavioral: Photo documentation of orolabial herpes lesions;   Behavioral: Completion of questionnaires (patient-reported outcomes);   Procedure: 28-day swabbing of orolabial region;   Procedure: Blood drawin gs Sponsor:   Heidelberg ImmunoTherapeutics GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2020 Category: Research Source Type: clinical trials